Abstract
Objective: The aim was to observe the level changes of adiponectin (ADPN) and CD146 in serum and clarify the properties of these peptides in patients with type 2 diabetic nephropathy (DN). Materials and Methods: Seventy-five patients with type 2 diabetes and 13 control subjects included in this study. Levels of ADPN and CD146 in serum were measured by enzyme-linked immunosorbent assay. Results: The serum level of ADPN was higher in patients with diabetes than that in controls, and it increased significantly in the DN1 group. The serum level of CD146 was considerably higher in the DN1 group than that in the other groups. The serum level of ADPN was positively correlated with the serum level of CD146 and body mass index in diabetics. The serum level of ADPN in 54 patients with diabetes and vascular atherosclerosis was significantly lower than that in 21 patients without vascular atherosclerosis. However, there was a definite relationship between the serum levels of ADPN and CD146. Conclusion: The serum levels of ADPN and CD146 appear to increase in patients with early DN and decrease in the final stage of DN. Serum ADPN and CD146 may protect against vascular endothelial dysfunction and mitigate endothelial dysfunction in DN. Further study is required to elucidate the exact role of ADPN and CD146 in the progression of vascular complication in DN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
